Experimental Pharmacological Agents for the Treatment of Primary Biliary Cholangitis

Experimental Pharmacological Agents for the Treatment of Primary Biliary Cholangitis

Annarosa Floreani1,2 1University of Padova, Padova, Italy; 2Scientific Institute for Research, Hospitalization and Healthcare, Negrar, Verona, ItalyCorrespondence: Annarosa FloreaniUniversity of Padova, Padova, ItalyTel +10393899418841Email annarosa.floreani@unipd.itAbstract: The standard therapy fo...

Full description

Bibliographic Details
Main Author:	Floreani A
Format:	Article
Language:	English
Published:	Dove Medical Press 2020-12-01
Series:	Journal of Experimental Pharmacology
Subjects:	pbc treatment ursodeoxycholic acid obeticholic acid fibrates fxr agonists ppar agonists
Online Access:	https://www.dovepress.com/experimental-pharmacological-agents-for-the-treatment-of-primary-bilia-peer-reviewed-fulltext-article-JEP

Similar Items

Update on the Pharmacological Treatment of Primary Biliary Cholangitis
by: Annarosa Floreani, et al.
Published: (2022-08-01)

Pharmacotherapy for primary biliary cholangitis: an assessment of medication candidacy and rates of treatment
by: Nicholas MacDonald, et al.
Published: (2024-01-01)

Primary biliary cholangitis
by: I. M. Iljinsky, et al.
Published: (2021-04-01)

Current and future opportunities for the management of primary biliary cholangitis
by: Sandra Naffouj, et al.
Published: (2023-12-01)

Update on Emerging Treatment Options for Primary Biliary Cholangitis
by: Aguilar MT, et al.
Published: (2020-05-01)

Obeticholic acid for the treatment of primary biliary cholangitis in adult patients: clinical utility and patient selection
by: Bowlus CL
Published: (2016-09-01)

Obeticholic Acid for Primary Biliary Cholangitis
by: Annarosa Floreani, et al.
Published: (2022-10-01)

New developments in the treatment of primary biliary cholangitis – role of obeticholic acid
by: Jhaveri MA, et al.
Published: (2017-08-01)

PPAR agonists for the treatment of primary biliary cholangitis: Old and new tales
by: Francesca Colapietro, et al.
Published: (2023-01-01)

Diagnosis and Treatment of Primary Biliary Cholangitis
by: Kyung-Ah Kim
Published: (2023-02-01)

Current Therapies for Cholestatic Diseases
by: Nahum Méndez-Sánchez, et al.
Published: (2023-06-01)

Fibrates for the Treatment of Primary Biliary Cholangitis Unresponsive to Ursodeoxycholic Acid: An Exploratory Study
by: Guilherme Grossi Lopes Cançado, et al.
Published: (2022-01-01)

The Management of Cholestatic Liver Diseases: Current Therapies and Emerging New Possibilities
by: Marta Mazzetti, et al.
Published: (2021-04-01)

Fenofibrate enhances lipid deposition via modulating PPARγ, SREBP-1c, and gut microbiota in ob/ob mice fed a high-fat diet
by: Ying Zhang, et al.
Published: (2022-09-01)

Multiple therapeutic targets in rare cholestatic liver diseases: Time to redefine treatment strategies
by: Alessio Gerussi, et al.
Published: (2020-01-01)

Primary Biliary Cholangitis and Bile Acid Farnesoid X Receptor Agonists
by: Ludovico Abenavoli, et al.
Published: (2020-06-01)

Impact of Primary and Secondary Bile Acids on Clostridioides difficile Infection
by: Łukawska Agata, et al.
Published: (2022-03-01)

Clinical, Molecular, and Histopathological Aspect of Primary Biliary Cholangitis
by: Flora Dameria, et al.
Published: (2020-07-01)

Farnesoid X Receptor as Target for Therapies to Treat Cholestasis-Induced Liver Injury
by: Anca D. Petrescu, et al.
Published: (2021-07-01)

Effects of Intestinal FXR-Related Molecules on Intestinal Mucosal Barriers in Biliary Tract Obstruction
by: Meng Yan, et al.
Published: (2022-06-01)

New Therapeutic Targets in Autoimmune Cholangiopathies
by: Alessio Gerussi, et al.
Published: (2020-04-01)

The Small Molecule PPARγ Agonist GL516 Induces Feeding-Stimulatory Effects in Hypothalamus Cells Hypo-E22 and Isolated Hypothalami
by: Annalisa Chiavaroli, et al.
Published: (2022-07-01)

Selected Aspects of the Intricate Background of Immune-Related Cholangiopathies—A Critical Overview
by: Beata Kasztelan-Szczerbinska, et al.
Published: (2023-02-01)

Features of Lipid Metabolism Disorders in Primary Biliary Cholangitis
by: Vasiliy I. Reshetnyak, et al.
Published: (2022-11-01)

Prognostic utility of albumin-bilirubin grade in Japanese patients with primary biliary cholangitis
by: Yuki Yamashita, et al.
Published: (2023-04-01)

The Surging Function of Nanotechnology in the Management of Primary Biliary Cholangitis with Obeticholic Acid
by: Devyani Patil, et al.
Published: (2023-05-01)

Impact of concomitant fibrates on immunotherapy outcomes for advanced non‐small cell lung cancer
by: William A. Stokes, et al.
Published: (2023-01-01)

Liver transplantation for primary biliary cholangitis (review)
by: I. M. Iljinsky, et al.
Published: (2022-04-01)

Machine learning prediction model for treatment responders in patients with primary biliary cholangitis
by: Naruhiro Kimura, et al.
Published: (2023-06-01)

Evaluation of the United Kingdom‐primary biliary cholangitis and global primary biliary cholangitis group prognostic models for primary biliary cholangitis patients treated with ursodeoxycholic acid in the U.S. population
by: Mohammad Alomari, et al.
Published: (2020-04-01)

NASH: A glance at the landscape of pharmacological treatment
by: Lucia Brodosi, et al.
Published: (2016-09-01)

Bile Acid Receptor Therapeutics Effects on Chronic Liver Diseases
by: Vik Meadows, et al.
Published: (2020-01-01)

Overlap syndrome of primary biliary cholangitis and primary sclerosing cholangitis: two case reports
by: Haythem Yacoub, et al.
Published: (2023-04-01)

Primary Biliary Cholangitis: Promising Emerging Innovative Therapies and Their Impact on GLOBE Scores
by: Sohal A, et al.
Published: (2023-06-01)

Bacterial and metabolic phenotypes associated with inadequate response to ursodeoxycholic acid treatment in primary biliary cholangitis
by: Laura Martinez-Gili, et al.
Published: (2023-12-01)

Current Perspectives on the Molecular and Clinical Relationships between Primary Biliary Cholangitis and Hepatocellular Carcinoma
by: Annarosa Floreani, et al.
Published: (2024-02-01)

Role of ductular reaction and ductular–canalicular junctions in identifying severe primary biliary cholangitis
by: Diletta Overi, et al.
Published: (2022-11-01)

Novel Insights of Primary Sclerosing Cholangitis and Primary Biliary Cholangitis
by: Dong-Won Ahn
Published: (2020-05-01)

FXR activation promotes intestinal cholesterol excretion and attenuates hyperlipidemia in SR‐B1‐deficient mice fed a high‐fat and high‐cholesterol diet
by: Amar B. Singh, et al.
Published: (2020-03-01)

Primary sclerosing cholangitis and pregnancy
by: Casper Q. Kammeijer, et al.
Published: (2011-08-01)